StreetInsider.com News Articles

Form 4 Larimar Therapeutics, For: Sep 29 Filed by: Harlow John B. Jr.

Thu, 01 Oct 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20261001/27136394.html

Form 3 Larimar Therapeutics, For: Sep 29 Filed by: Harlow John B. Jr.

Thu, 01 Oct 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20261001/27136378.html

Form 8-K Larimar Therapeutics, For: Sep 29

Tue, 29 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260929/27122464.html

Larimar Therapeutics names John Harlow as president and COO

Tue, 29 Sep 2026 16:05:22 -0400

Larimar Therapeutics, Inc. (NASDAQ: LRMR) appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, according to a company statement. Harlow will report to Chief Executive Officer Carole Ben-Maimon, M.D.

Harlow brings more than 25 years of experience in commercial, operational, and business development roles across the biopharmaceutical industry. Most recently, he served as Chief Commercial Officer at Esperion Therapeutics, where he led commercial operations, business development, and global alliance management. Before that, he held the same title at Melinta Therapeutics prior to its 2025 acquisition by CorMedix.

Earlier roles include executive positions at Baudax Bio, Recro Pharma, and

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Tue, 29 Sep 2026 16:05:00 -0400

BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.

“As nomlabofusp advances toward potential approval, we are excited to welcome John to our executive team,” said Carole Ben-Maimon, M.D., Chief Executive

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Tue, 29 Sep 2026 16:05:00 -0400

“As nomlabofusp advances toward potential approval, we are excited to welcome John to our executive team,” said Carole Ben-Maimon, M.D., Chief Executive

Leerink Starts Larimar Therapeutics (LRMR) at Outperform

Mon, 14 Sep 2026 06:06:51 -0400

Leerink analyst Joseph Schwartz initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Outperform rating and a price target of $13.00.

For an analyst ratings summary and ratings history on Larimar Therapeutics click here. For more ratings news on Larimar Therapeutics click here.

Shares of Larimar Therapeutics closed at $3.92 yesterday.

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Truitt currently serves as chief executive officer and board member of iECURE, Inc., a clinical-stage biotechnology company focused on genome-editing therapies. He also serves as chairman of the board of Larimar Therapeutics (NASDAQ: LRMR) and as a board member of Code Biotherapeutics.

Previously, Truitt was chief executive officer of BioSpecifics Technologies Corp. until its acquisition by Endo International plc in December 2020. Before that, he held several roles at Achillion Pharmaceuticals, including chief commercial officer, chief operating officer, and chief executive officer, prior to

Century Therapeutics names Joseph Truitt to its board of directors

Wed, 09 Sep 2026 16:05:19 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Joseph Truitt to its board of directors, the biotechnology company announced.

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors.

Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing genome-editing therapies for rare, life-threatening genetic diseases. He is Chairman of the Board of Larimar Therapeutics (NASDAQ: LRMR) and a member of the Board of Directors of Code

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Century Therapeutics Appoints Joseph Truitt to Board of Directors

Wed, 09 Sep 2026 16:05:00 -0400

Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 8c

Tue, 04 Aug 2026 07:24:56 -0400

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

Form 10-Q Larimar Therapeutics, For: Jun 30

Tue, 04 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260804/26861487.html

Form 10-Q Larimar Therapeutics, For: Jun 30

Tue, 04 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260804/26861487.html

Form 8-K Larimar Therapeutics, For: Aug 04

Tue, 04 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26861396.html

Form 8-K Larimar Therapeutics, For: Aug 04

Tue, 04 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26861396.html

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Tue, 04 Aug 2026 07:00:00 -0400

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures
High patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end
Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion expected 2H 2026
Dosing of first patient in global confirmatory Phase 3 study expected Q3 2026
$156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, with projected cash runway